Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Lawsuit Seeks To Force FDA's Hand On Lipitor Generics

This article was originally published in The Pink Sheet Daily

Executive Summary

Company files for an injunction requiring FDA to announce whether Ranbaxy's atorvastatin ANDA is ineligible for 180-day marketing exclusivity, a determination that could clear the path for approval of other applications starting June 28.
Advertisement

Related Content

Lipitor Generics Watch: FDA Has Yet To Approve ANDA For The World's #1 Drug
Lipitor Generics Watch: FDA Has Yet To Approve ANDA For The World's #1 Drug
Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA
Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA
Lipitor Generics: Judge Questions Mylan's Right To Sue Over Ranbaxy Marketing Exclusivity
Lipitor Generics: Judge Questions Mylan's Right To Sue Over Marketing Exclusivity
Lipitor Generics: FDA Says Mylan Has No Standing To Sue (Until June 28?)
Lipitor Generic Bottleneck Needs To Be Cleared "Now," Senators Tells FDA
Lipitor Generic Bottleneck Needs To Be Cleared "Now," Senators Tells FDA
The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics

Topics

Advertisement
UsernamePublicRestriction

Register

PS071988

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel